Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
PROM (PROM) 24-hour volatility at 85.9%: Surge in trading volume accompanies futures liquidation

PROM (PROM) 24-hour volatility at 85.9%: Surge in trading volume accompanies futures liquidation

Bitget PulseBitget Pulse2026/04/18 20:24
Show original
By:Bitget Pulse

Volatility Overview

PROM experienced dramatic price fluctuations over the past 24 hours, with a low of $1.56 and a high of $2.90. It is currently quoted at $2.003, with a swing of as much as 85.9%. The total amount of liquidations across all futures platforms reached $36,447, reflecting active leveraged trading.

Brief Analysis of the Causes

- No official announcements, partnerships, or significant on-chain whale transfer events were observed in the past 24 hours.

- Futures platform data shows total PROM positions liquidated across the network amount to $36,447, which may have amplified price volatility.

- Trading activity has increased, and some platforms report 24-hour volatility as high as 41.5%, accompanied by a significant surge in trading volume.

Market Views and Outlook

Market sentiment towards PROM's abnormal fluctuations is divided; some platforms regard it as a highly volatile profit opportunity in the Layer 2 sector, but with associated liquidation risks. Mainstream data indicates the current price is oscillating between $2.12 and $2.23, and short-term further liquidation pressure should be watched closely.

Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring. For informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16